Bio-Path Holdings (BPTH)

$2.68 0.05 (1.71%)

16:00 EDT BPTH Stock Quote Delayed 30 Minutes

Why Is Bio-Path (BPTH) Stock Up 89% Today?

By William White, InvestorPlace Writer Apr 18, 2024

Bio-Path stock is up with heavy trading of BPTH shares today alongside positive news from its ongoing clinical trial of BP1002.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Why Is Bio-Path (BPTH) Stock Down 12% Today?

More Articles

Volume:

Previous Close -

Market Cap 1.82M

PE Ratio -0.08

EPS -33.63

Volume (Avg. Vol.) 117,216

Day's Range $2.45 - $2.80

52-Week Range $0.32 - $7.67

Dividend & Yield N/A (N/A)

BPTH Stock Predictions, Articles, and Bio-Path Holdings News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Jun 26, 2023

It's time to start off the week right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Apr 13, 2022

Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday!

BPTH Stock: The Good News That Has BioPath Investors Smiling Today

By William White, InvestorPlace Writer Aug 24, 2021

BioPath (BPTH) stock is soaring higher on Tuesday after revealing an update from the FDA on its IND application for BP1002.

BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Than 20%

By Brenden Rearick, InvestorPlace Financial News Writer Aug 24, 2021

BPTH stock is shooting up this morning as the company reveals a new plan for evaluating the effectiveness of one of its drugs.

BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today

By William White, InvestorPlace Writer Feb 10, 2021

Bio-Path Holdings (BPTH) stock is rocketing higher on Wednesday after announcing patent updates for its DNAbilize platform.

Bio-Path Holdings News: Why BPTH Stock Is Soaring Today

By Nick Clarkson, Web Editor Oct 22, 2020

BPTH stock received a boost on Thursday after Bio-Path received a notice of allowance for a strategic patent for its candidate Prexigebersen.

Bio-Path Earnings: BPTH Stock Moves on Q3 Results

By William White, InvestorPlace Writer Nov 15, 2019

Bio-Path (BPTH) earnings for the biotechnology company's third quarter of 2019 saw BPTH stock taking a wild ride on Friday.

3 Big Stock Charts for Tuesday: Hanesbrands, Omnicom Group and Schlumberger

By James Brumley, InvestorPlace Feature Writer Apr 16, 2019

The stock charts of SLB, HBI and OMC have earned a closer technical look headed into today's trading action.

Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today

By William White, InvestorPlace Writer Apr 15, 2019

Bio-Path Holdings news about the company not offering additional shares of its stock as previously planned has BPTH up on Monday.

Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons

By Josh Enomoto, InvestorPlace Contributor Mar 21, 2019

BPTH stock is easily one of 2019's top performers, but you’ve got to look at the whole Bio-Path story before jumping aboard.

Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today

By William White, InvestorPlace Writer Mar 6, 2019

Recent Bio-Path Holdings news concerning a clinical update for a Phase 2 trial has BPTH stock flying high as of Wednesday.

Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today

By William White, InvestorPlace Writer Apr 3, 2018

Bio-Path (BPTH) stock was up Tuesday after the company announced financial data for 2017 and interim results for a Phase 2 study.

Bio-Path announces 1-for-20 reverse stock split, effective Feb 22 (NASDAQ:BPTH)

From Seeking Alpha Feb 21, 2024

Bio-Path Holdings announces a 1-for-20 reverse stock split, effective Feb 22, 2024.

Bio-Path files to sell shares (NASDAQ:BPTH)

From Seeking Alpha Dec 22, 2023

Bio-Path files prospectus for public offering of shares and warrants, but it is not an offer to sell securities.

Analysts Offer Insights on Healthcare Companies: Bio-Path Holdings (BPTH), Argenx Se (ARGX) and Revolution Medicines (RVMD)

From TipRanks Dec 8, 2022

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bio-Path Holdings (BPTH – Research Report), Argenx S...

H.C. Wainwright Reaffirms Their Buy Rating on Bio-Path Holdings (BPTH)

From TipRanks Nov 15, 2022

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings (BPTH – Research Report) today and set a price target of $9.00. The company&#8217...

Bio-Path Holdings (BPTH) Receives a Buy from H.C. Wainwright

From TipRanks Oct 27, 2022

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bio-Path Holdings (BPTH – Research Report), with a price target of $9.00. ...

Bio-Path Holdings (BPTH) Gets a Buy from H.C. Wainwright

From TipRanks Aug 17, 2022

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings (BPTH – Research Report) today and set a price target of $9.00. The company&#8217...

ADVERTISEMENT